UCSF Health | Strategic Alliance Partners

"We think this is an important call to action for the NCCN to follow in the footsteps of the AUA, who recently removed VLR from its prostate cancer guidelines in its most recent update," says Kevin Shee, MD, PhD.

"[Although] American Indian/Alaskan Native patients do present with more advanced prostate cancer, show lower rates of definitive treatment, and higher mortality, once we adjust for some of these disparities in access, we found that there were no significant differences in mortality," says Carissa E. Chu, MD.

In this interview, Ira Sharlip, MD, explains the potential dangers these products pose and what urologists can do to help protect their patients.

“We found many factors in urology that were associated with the inability to follow through with a video visit,” says Kevin Shee, MD, PhD.

"[Low-grade prostate cancer] is a really interesting field right now," says Kevin Shee, MD, PhD.

“As people think about how we can do stone surgery more effectively, less morbidly for our patients, and less invasively, I think we're going to see robots enter our picture,” says Thomas Chi, MD.

“We've got a lot of movement in terms of understanding how stones form, some pharmaceutical interventions that we can use to prevent stones, and then how we can get even less invasive to try to get stones in the least morbid way for our patients,” says Thomas Chi, MD.

Dr. Butler discusses 2022 milestones from her practice in gender-affirming care and looks ahead to what might be on the horizon for the field in the coming year.

Thomas Chi, MD, discusses 2022 milestones in stone disease and looks ahead to what might be on the horizon for the field in the coming year.

"We're trying to figure out how to improve people's relationships with their genitals and like their sexual practices," says Christi Butler, MD.

Dr. Van Kuiken discusses 2022 milestones in FPMRS and looks ahead to what might be on the horizon for the field in the coming year.

“We were able to develop a machine learning model that had decent accuracy…in predicting which patients would have an additional stone event and which patients wouldn't,” says Kevin Shee, MD, PhD.

Join the discussion on Health Reform with world leader in health policy and bioethics, Ezekiel J. Emanuel, MD, PhD, the Vice Provost for Global Initiatives and expert panelists and UCSF leaders.

"HP 13C MRI provides a quick five-minute, non-radioactive, metabolic imaging add-on exam to standard-of-care MRI that, in conjunction with guided biopsies, has great potential to improve the care of prostate cancer patients,” said Robert Bok, MD, PhD.

The phase 3 PRESTO trial had 3 arms: ADT alone; ADT plus apalutamide; and ADT plus apalutamide plus abiraterone/prednisone.

“We wanted to compare outcomes between nursing home residents and community-dwelling older adults undergoing surgery for bladder and bowel dysfunction,” explains Anne M. Suskind, MD.

“It’s hard to see yourself in a field when there are not that many residents or faculty that look like you,” says Micha Cheng, MD, MPH, MS.

Micha Yin-Zheng Cheng, MD, MPH, MS, discusses the background of the UCSF UReTER (UnderRepresented Trainees Entering Residency) Mentorship Program.

Eric J. Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.

“I think we often encourage our patients to share concerns about depression, anxiety, and other mental health conditions, yet are less likely ourselves to seek help due to this issue of stigma,” says Raj S. Pruthi, MD, MHA, FACS.

The study showed that the PSMA-targeting fluorophore IS-002 enabled enhanced intraoperative tumor detection during robotic prostatectomy.

“Not only does a deep PSA response identify patients who will have improved survival and progression-free outcomes, but also it is also associated with maintenance of health-related quality of life, improved patient reported physical wellbeing, and a reduced risk of worsening pain and fatigue intensity,” said Eric Jay Small, MD.

Anne M. Suskind, MD, highlights her presentation, “Mentorship as a Team Sport,” from the 2022 Society of Women in Urology Annual Clinical Mentoring Conference.

“Open your mind to being both [a mentee and mentor,] no matter where you are,” says Anne M. Suskind, MD, MS, FACS, FPMRS.

"Clinicians taking care of patients with high-risk prostate cancer being assessed for prostatectomy can use a positive [PSMA] PET scan as a true positive, whereas a negative scan cannot be used to exclude disease or inform nodal dissection," wrote Joseph Osborne, MD, PhD, and colleagues.

"As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on," says Anne M. Suskind, MD, MS, FACS, FPMRS.

As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on,” says Anne M. Suskind, MD, MS, FACS, FPMRS.

In a recent study presented at the 2021 AUA Annual Meeting, Scarlett Gomez, MPH, PhD, and co-authors investigated the determinants of selecting active surveillance/watchful waiting as a treatment path for patients with localized, low-risk prostate cancer.

“This type of collaboration [between SEER and GPS assay] is a really nice illustration of the types of projects that we should be undertaking in the future,” says Scarlett Gomez, MD, PhD.

“We're increasingly seeing the addition of molecular and genetic tests to guide us in terms of the cancer treatment that we provide our patients,” says Scarlett Gomez, MD, PhD.